[Efficacy studies] [0.03%]
[疗效研究]
Juan Pedro-Botet,Juana A Flores-Le Roux
Juan Pedro-Botet
Pravafenix(®) is a fixed-dose combination of 40mg of pravastatin and 160 mg of fenofibrate. The rationale behind the use of Pravafenix(®) is based on the increased residual cardiovascular risk observed in high risk patients with hypertrig...
[The fixed combination of pravastatin and fenofibrate: what can it provide?] [0.03%]
普伐他汀与非诺贝特的定速复方有什么优势？
Ángel Díaz Rodríguez
Ángel Díaz Rodríguez
The treatment of patients with high cardiovascular risk and mixed hyperlipidemia is difficult due to multiple quantitative and qualitative lipid abnormalities. The priority is to reduce LDL-c levels, for which statins are the drug of choice...
[The combinations of statins and fibrates: pharmacokinetic and clinical implications] [0.03%]
他汀类与贝特类联合应用的药动学和临床意义
Pedro González Santos
Pedro González Santos
With mixed dyslipidemia of the atherogenic dyslipidemia type, once the LDL-c objectives have been achieved through statin treatment, there is often a residual risk, for which the addition of a fibrate is recommended. The combination of stat...
[Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol] [0.03%]
治疗脂质异常的新靶点-高密度和非高密度胆固醇水平
Ángel Julián Brea Hernando
Ángel Julián Brea Hernando
Atherogenic dyslipidemia (AD) consists of the combination of an increase in very low density lipoproteins (VLDL), which results in increased plasma triglyceride (TG) levels, with a reduction of levels of high-density lipoprotein bound chole...
[Introduction. Justification] [0.03%]
[引言。理由]
Jesús Millán Núñez-Cortés
Jesús Millán Núñez-Cortés
[Interaction of FABP4 with plasma membrane proteins of endothelial cells] [0.03%]
[FABP4与内皮细胞膜蛋白相互作用]
Paula Saavedra,Josefa Girona,Gemma Aragonès et al.
Paula Saavedra et al.
Introduction: Fatty acid binding protein (FABP4) is an adipose tissue-secreted adipokine implicated in the regulation of the energetic metabolism and inflammation. High levels of circulating FABP4 have been described in p...
[Atorvastatin inhibits the atherosclerotic lesion induced by tumor necrosis factor-like weak inducer of apoptosis in apolipoprotein E deficient mice] [0.03%]
阿托伐他汀干预TWIKA5诱导的载脂蛋白E基因缺陷小鼠动脉粥样硬化病变的研究
Valvanera Fernández-Laso,Cristina Sastre,Jesús Egido et al.
Valvanera Fernández-Laso et al.
Aim: Interaction of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) with its receptor Fn14 accelerates atherosclerotic plaque development in ApoE deficient mice (ApoE KO). In this work, an analysis has been m...
[Coronary calcification as a predictor of risk in percutaneous coronary intervention] [0.03%]
冠脉钙化量预测经皮冠状动脉介入风险的临床研究
Efrén Martínez-Quintana,Fayna Rodríguez-González
Efrén Martínez-Quintana
Juan Pedro-Botet,Jesús Millán Núñez-Cortés
Juan Pedro-Botet
Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception [0.03%]
动脉粥样硬化性脂质异常症在中危至高危心血管病患者中的患病率及其心血管风险感知状况
Nuria Plana,Daiana Ibarretxe,Anna Cabré et al.
Nuria Plana et al.
Introduction: Atherogenic dyslipidemia is an important risk factor for cardiovascular disease. We aim to determine atherogenic dyslipidemia prevalence in primary care patients at moderate-very high cardiovascular risk and...